Form 4 for IDXX Idexx Laboratories
Accepted 2025-08-11 00:00:00 ET · period of report 2025-08-07 · accession 0000874716-25-000129 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-08-11 | 2025-08-07 | IDXX | Emerson Andrew | EVP, CFO, Treas | M - OptEx | $141.60 | +1,849 | 4,273 | +76% | +$261.8K |
| D | 2025-08-11 | 2025-08-07 | IDXX | Emerson Andrew | EVP, CFO, Treas | F - Tax | $650.06 | -402 | 3,871 | -9% | -$261.3K |
| D | 2025-08-11 | 2025-08-07 | IDXX | Emerson Andrew | EVP, CFO, Treas | M - OptEx | — | -1,849 | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-07 | M | A | 1,849 | $141.60 | 4,272.78 | D | — | — | (F1) Includes a total of 27.3420 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. |
| 2 | Common | Common Stock | 2025-08-07 | F | D | 402 | $650.06 | 3,870.78 | D | — | — | |
| 3 | Derivative | Incentive Stock Option (right-to-buy) | 2025-08-07 | M | D | 1,849 | — | 0 | D | $141.60 · — to 2027-02-13 | 1,849 Common Stock | (F3) Not applicable. (F2) Grant of option to buy 1,849 shares of Issuer common stock that vested on February 14, 2022. |